Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62

Oppenheimer analyst Jeff Jones has maintained an 'Outperform' rating on Pelthos Therapeutics (AMEX: PTHS) and raised the price target from $60 to $62. This adjustment reflects a positive outlook for the company's performance in the market.